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Abstract
Objectives To analyze kidney injury molecule-1 (KIM-1) and
neutrophil gelatinase-associated lipocalin (N-GAL) excretion
post-intravenous contrast enhanced-CT (CE-CT) in patients
with chronic kidney disease (CKD).
Methods Patients were enrolled in a trial on hydration regimes
to prevent contrast-induced acute kidney injury (CI-AKI).
Blood and urine samples were taken at baseline, 4 – 6, and
48 – 96 h post CE-CT. Urinary KIM-1 and N-GAL values
were normalized for urinary creatinine levels, presented as
medians with 2.5 – 97.5 percentiles.
Results Of the enrolled 511 patients, 10 (2 %) were lost to
follow-up. CI-AKI occurred in 3.9 % of patients (20/501).
Median KIM-1 values were 1.2 (0.1 – 7.7) at baseline, 1.3
(0.1 – 8.6) at 4 – 6 h, and 1.3 ng/mg (0.1 – 8.1) at 48 – 96 h
post CE-CT (P=0.39). Median N-GAL values were 41.0 (4.4
– 3,174.4), 48.9 (5.7 – 3,406.1), and 37.8 μg/mg (3.5 – 3,
200.4), respectively (P=0.07). The amount of KIM-1 and N-
GAL excretion in follow-up was similar for patients with and
without CI-AKI (P-value KIM-1 0.08, P-value N-GAL 0.73).
Neither patient characteristics at baseline including severe
CKD, medication use, nor contrast dose were associated with
increased excretion of KIM-1 or N-GAL during follow-up.
Conclusion KIM-1 and N-GAL excretion were unaffected by
CE-CT both in patients with and without CI-AKI, suggesting
that CI-AKI was not accompanied by tubular injury.
Key Points
• KIM-1 and N-GAL excretion were unaffected by intravenous
contrast-enhanced CT (CE-CT).
• Patient or procedure characteristics were not associated
with increased KIM-1 or N-GAL excretion.
• Performance of CE-CT in CKD patients is likely to be safe.
Keywords Acute kidney injury . Contrast media . Renal
insufficiency, chronic . Biological markers .Multidetector
computed tomography
Introduction
Contrast-induced acute kidney injury (CI-AKI) is an acute de-
cline in renal function following administration of iodinated con-
trast media [1, 2]. CI-AKI occurs in 5 – 6 % of patients under-
going intravenous contrast enhanced computed tomography
(CE-CT), a very common procedure worldwide [3, 4].
Although the definition of CI-AKI is the subject of debate, all
proposed criteria are based on changes in serum creatininewithin
a few days following contrast administration [5]. However,
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serum creatinine is regarded as a non-specific marker for CI-AKI
since several mechanisms (i.e. use of medication, hemodynam-
ics, and comorbidity such as peripheral artery disease or diabe-
tes) can also influence its value [1, 6, 7]. The clinical significance
of serum creatinine changes post CE-CT has become disputable
after publication of studies suggesting that fluctuations in serum
creatinine occur as frequent in patients undergoing CE-CT, as in
those not receiving contrast media [8, 9]. However, physicians
are still concerned about the risk of CI-AKI and are hesitant to
use CE-CT in their diagnostic workup, especially in patients with
pre-existing chronic kidney disease (CKD) [8]. Knowledge
about the risk of renal injury post-CE-CT is, therefore, of clinical
importance and may be derived from studies measuring bio-
markers of acute kidney injury in the context of CI-AKI, such
as kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-
associated lipocalin (N-GAL). These biomarkers have been
proven to be predictive of CI-AKI in the setting of percutaneous
coronary interventions requiring intra-arterial contrast adminis-
trations [10–16]. Yet, although N-GAL excretion has been ana-
lyzed in a small cohort of patients undergoing CE-CT, these
biomarkers have not been studied thoroughly within this popu-
lation. Hence, the aim of our study was to investigate KIM-1 and
N-GAL excretion and their association with the occurrence CI-
AKI after CE-CT in patients with pre-existing CKD.
Methods
Study patients were enrolled in a randomized controlled trial
on CI-AKI preventing hydration regimes between January
2010 and June 2012 in four Dutch hospitals (Leiden
University Medical Center, Leiden, Bronovo Hospital, The
Hague, St. Lucas Andreas Hospital, Amsterdam, and St.
Antonius Hospital, Nieuwegein). Patients electively
underwent CE-CT and were randomized to either 250 ml
1.4 % sodium bicarbonate hydration 1 h prior to CE-CT or
standard treatment with 1,000 ml 0.9 % saline during 4 to 12 h
prior to and after CE-CT. No other CI-AKI preventive treat-
ments were used, such as administration of N-acetylcysteine.
Patients were 18 years or older, eligible to receive the fluid
challenge of saline hydration, and had an estimated glomeru-
lar filtration rate (eGFR)<60 ml/min. eGFR values were cal-
culated using the abbreviate modification of diet in renal dis-
ease (MDRD) formula [17]. Exclusion criteria were docu-
mented allergy for iodinated contrast media, pregnancy, pre-
vious contrast administrations within 7 days prior to CE-CT,
and hemodynamic instability. In addition to the general exclu-
sion criteria for the trial, patients in whomCTwas cancelled or
unexpectedly performed without intravenous contrast admin-
istration were also excluded for the current analysis. Type of
contrast media used at time of CE-CT was according to clin-
ical practice in the participating hospitals and varied between
Iomeprol (Iomeron, Bracco Imaging, Milan, Italy), Iobitridol
(Xenetix, Guerbet, Aulnay-sous-Bois, France), or Iodixanol
(Visipaque, GE Healthcare, Chalfort St. Giles, UK). An inde-
pendent data and safety monitoring board periodically
reviewed study outcomes. All patients provided written in-
formed consent and the protocol of the trial was approved
by the institutional review boards of each of the participating
centres. The trial was performed according to the declaration
of Helsinki and was registered with the Netherlands Trial
Register, NTR 2149.
Materials
Serum and urine samples were collected prior to hydration,
and once between 4 – 6 and 48 – 96 h post-CE-CT for anal-
yses of serum creatinine and urinary creatinine, KIM-1 and N-
GAL levels. Urinary creatinine levels were used to correct
KIM-1 and N-GAL values for dilution as a result of the two
hydration regimes [18]. Therefore, analyses were made using
N-GAL/urine creatinine and KIM-1/urine creatinine ratios,
which will be revered to as KIM-1 (in ng/mg) and N-GAL
(μg/mg) excretion. Serum and urine samples were also col-
lected 2 months post-CE-CT for patients developing CI-AKI,
to determine whether renal function had recovered.
Furthermore, information on patient characteristics at base-
line, use of nephrotoxic medication and injected contrast vol-
umes were collected.
Outcomes and Definitions
Primary outcomes of our study were relative changes in KIM-
1 and N-GAL excretion post CE-CT as compared with base-
line. Furthermore, we studied whether changes in KIM-1 and
N-GAL excretion post-CE-CT correlated to changes in serum
creatinine or the occurrence of CI-AKI. CI-AKI was defined
by an increase in serum creatinine over 25 % or 44 μmol/L
(0.5 mg/L) within 48 – 96 h post-CE-CT. Renal function was
considered recovered if the increase in serum creatinine
2 months post-CE-CT no longer exceeded these thresholds.
Laboratory Methods
All samples were stored at -80 °C. Serum and urine creatinine
levels were analyzed using Roche Diagnostics, Mannheim,
Germany. Urinary KIM-1 and N-GAL values were analyzed
using ELISA (R&D systems, DuoSets Human TIM-1/KIM-1/
HAVCR and Lipocalin-2/N-GAL, MN, USA).
Statistical Analyses
KIM-1 and N-GAL excretion at 4 – 6 and 48 – 96 h post-CE-
CT were compared with baseline using linear mixed models
based on log-transformed KIM-1 and N-GAL values as they
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were non-normally distributed among the population. The ba-
se linear mixed model contained random subject effects and
fixed effects of time (categorical), randomization, and their
interaction. To study whether baseline conditions or contrast
dose were associated with changes in KIM-1 and N-GAL
excretion during follow-up, these factors and their interaction
with time were added to the base model. Correlation studies
were performed on the association between changes in serum
creatinine and in KIM-1 and N-GAL excretion at 4 – 6 and 48
– 96 h post-CE-CTcompared with baseline, using Spearman’s
correlation tests, and reported as correlation terms with corre-
sponding P-values. The area under the receiver operating
curve (ROC) was calculated under nonparametric assumption,
to analyze the predictive value of KIM-1 and N-GAL excre-
tion for the occurrence of CI-AKI measured at baseline, 4 – 6
and 48 – 96 h post-CE-CT. P-values<0.05 were considered
statistically significant. All statistical analyses were performed
using SPSS version 20.
Results
Study population
A total of 570 patients provided written informed consent. Of
those, 22 patients withdrew their consent and CT was per-
formed without intravenous contrast administration or can-
celled in 37 patients. As a result, the total population for this
analysis comprises 511 patients of whom 10 (2.0 %) where
lost to follow-up for the endpoint of CI-AKI. Patient charac-
teristics at baseline are reported in Table 1. Mean relative
increase in serum creatinine 48 – 96 h post-CE-CT compared
with baseline was 1.2 % (SD 13.3 %). CI-AKI occurred in
3.9 % of patients (20/501, 95 % CI 2.6 – 6.1 %). Renal func-
tion recovered within 2 months post-CE-CT in 13 out of 19
(68.0 %) patients diagnosed with CI-AKI and one patient was
lost to follow-up. None of the patients developing CI-AKI had
a need for renal replacement therapy within 2 months after
CE-CT.
N-GAL and KIM-1 excretion
Baseline KIM-1 and N-GAL values correlated well with
KIM-1 (Spearman’s rho 0.83, P<0.001) and N-GAL excre-
tion adjusted for dilution by urine creatinine (Spearman’s rho
0.87, P<0.001) (Fig. 1 a, b). Median KIM-1 and N-GAL
excretion at baseline, 4 – 6 h and 48 – 96 h post-CE-CT are
reported in Table 2. Figures 2 and 3 reflect KIM-1 and N-GAL
excretion in patients with and patients without CI-AKI at A)
baseline, B) 4 – 6 h, and C) 48 – 96 h post-intravenous con-
trast-enhanced computed tomography. Both KIM-1 and N-
GAL excretion remained unchanged during follow-up within
the total population. Additionally, the relative change in KIM-
1 and N-GAL excretion during follow-up was similar for pa-
tients with and without CI-AKI (P-value for KIM-1 excre-
tion=0.08 and for N-GAL excretion=0.73), suggesting that
CI-AKI post-CE-CTwas not associated with tubular epithelial
damage. No correlations were found between an increase in
serum creatinine and N-GAL excretion 4 – 6 h (correlation
term -0.12, P=0.18), and 48 – 96 h post-CE-CT (correlation
term -0.04, P=0.51), or between an increase in serum creati-
nine and KIM-1 excretion at the same time points (correlation
term 0.07, P=0.17, and 0.08, P=0.12, respectively).
Regression analysis was performed to identify subgroups of
patient susceptible for changes in KIM-1 and N-GAL excre-
tion post-CE-CT, the results of which are reported in Table 3.
Neither patient characteristics at baseline including severe
CKD (i.e. eGFR<30 ml/min), medication use, type of hydra-
tion regime, nor contrast dose were associated with changes in
KIM-1 or N-GAL excretion during follow-up.
Table 1 Patient characteristics at baseline
N 511
Mean age, years 72.3 (9.4)
Sex, male 308 (60.3)
Outpatients 478 (93.5)
Mean eGFR ml/min 50.7 (13.8)
eGFR>45 ml/min 354 (69.3)
eGFR 30-45 ml/min 121 (23.7)
eGFR<30 ml/min 36 (7.0)
Hypertension 256 (50.1)
Diabetes mellitus 137 (26.8)
Peripheral artery disease 168 (32.9)
Coronary artery disease 175 (34.2)
Congestive heart failure 87 (17.0)





Angiotensin II receptor blockers 101 (19.8)
Chemotherapy 11 (2.2)
Preprocedural stop of medication 117 (22.9)
Type of CT-scan
CT abdomen 167 (32.7)
CT thorax 46 (9.0)
CT angiography 190 (37.2)
CT thorax-abdomen 29 (5.7)
CT kidney-pelvis 43 (8.4)
Other 36 (7.05)
Mean contrast volume, ml 105.2 (21.3)
Data are presented as mean (SD), or n (%)
eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease;
NSAIDs, non-steroidal anti-inflammatory drugs
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Diagnostic test characteristics
We calculated the diagnostic value of KIM-1 and N-GAL
excretion at baseline, 4 – 6 and 48 – 96 h post-CE-CT for
the endpoint of CI-AKI (Table 4). Overall, the performance
of the biomarkers was poor, with the highest area under the
ROC for N-GAL excretion measured between 48 – 96 h post-
CE-CT (area 0.63, 95 % CI 0.45 – 0.80).
Discussion
In the present study, we show that KIM-1 and N-GAL excre-
tion were unaffected by CE-CT in CKD patients both with and
without CI-AKI. This finding suggests that CE-CT was not
accompanied by tubular injury.
The American College of Radiology and the European
Society of Urology and Radiology guidelines on CI-AKI pre-
vention state that the risk of CI-AKI is lower after CE-CT
compared with intra-arterial contrast administration and that
therefore, preventive hydration can be withheld in either all
CKD patients [19], or at least in those with CKD stage 3A or
less (i.e. eGFR>45 – 60 ml/min) [2] undergoing CE-CT. The
level of evidence for these guideline recommendations is low,
as theywere based on retrospective studies comparing patients
undergoing CE-CT with a control group not receiving iodin-
ated contrast media, showing similar risks of acute kidney
injury in both groups [9, 20–23]. However, these studies were
prone for confounding by factors associated with the indica-
tion for contrast media use despite their attempts to adjust for
this matter, and their results are, therefore, difficult to gener-
alize into clinical practice [24].
The current understanding of the pathophysiology of CI-
AKI is based on tubular injury due to direct toxic effects of
contrast agents and secondary tubular injury due to ischemia.
We used a valid method to study contrast media induced tubu-
lar injury, bymeasuringKIM-1 andN-GAL excretion post-CE-
CT, two well-known biomarkers of CI-AKI as shown by sev-
eral studies among patients undergoing percutaneous coronary
interventions [11, 13–16]. Our study results suggest that in both
CKD patients with and without CI-AKI, signals for tubular
injury post-CE-CT are lacking. Hence, changes in serum creat-
inine post-CE-CT might be harmless, and possibly the result of
interplay between contrast media-induced vasoconstriction [1],
a b
Fig. 1 Correlation between A) KIM-1 and KIM-1/urine creatinine at baseline, and B) N-GAL and N-GAL/urine creatinine at baseline
Table 2 KIM-1 and N-GAL excretions during follow-up
Baseline 4 – 6 h post-CE-CT 48 – 96 h post-CE-CT P-value
KIM-1 ratio in ng/mg* 1.2 (0.1 – 7.7) 1.3 (0.1 – 8.6) 1.3 (0.1 – 8.1) 0.39
N-GAL in ug/mg † 41.0 (4.4 – 3,174.4) 48.9 (5.7 – 3,406.1) 37.8 (3.5 – 3,200.4) 0.07
Data are presented as median with 2.5 – 97.5 percentiles
*Values available at baseline in 431/511, at 4 – 6 h in 440/511, and at 48 – 96 h post-CE-CET in 401/511
†Values available at baseline in 417/511, at 4 – 6 h in 419/511, and at 48 – 96 h post-CE-CT in 388/511
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daily intra-individual variations in serum creatinine [24], and
co-morbidity affecting serum creatinine values. Our study,
therefore, challenges the creatinine-based definition of CI-AKI.
Only two prior studies reported on N-GAL expression post
CE-CTand found significant increases in urinary N-GAL after
6 and 8 h, respectively [25, 26]. However, in the first study,
CI-AKI occurred in 23/60 (23 %) patients, which is much
higher than the 5 – 6 % reported by two meta-analyses and
the 3.9 % observed in our study [4, 27]. It is, therefore, ques-
tionable whether this study is representative of the general
CKD population undergoing CE-CT in daily practice. The
second study only included inpatients (n=47), who might be
more prone to develop AKI due to other causes than contrast
media administration, which was also reflected by the 8.5 %
incidence of CI-AKI [26].
The KIM-1 receptor has been proposed to have two differ-
ent functions [28]. First, KIM-1 serves as a phagocytic
receptor on tubular cells contributing to repair processes [28,
29]. Second, KIM-1 might also have an inflammatory modu-
lating role attracting macrophages, monocytes, and fibroblast
to the region where epithelium cells are damaged [28]. The
exact working mechanism of N-GAL is unclear, although it
has been proposed that N-GAL limits tubular injury by mod-
ulation of cellular responses such proliferation, apoptosis, and
differentiation [30, 31].
In contrast with our results, studies on KIM-1 and N-GAL
excretion after intra-arterial contrast injections (not
intravenous such as for CE-CT) did find increased levels of
these biomarkers during follow-up [11, 13–16]. One of these
studies reported absence of an association between N-GAL
excretion and adverse clinical outcomes after coronary angi-
ography, whereas the other studies did not report results on the
association between increased KIM-1 or N-GAL excretion
and adverse clinical outcomes. Therefore, the clinical
Fig. 2 Figures reflect KIM-1 excretions in patients with (in green) and patients without (in blue) contrast-induced acute kidney injury atA) baseline, B) 4
– 6 h, and C) 48 – 96 h post-intravenous contrast-enhanced computed tomography
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relevance of the increased KIM-1 or N-GAL excretion found
after intra-arterial contrast administration in terms of long-
term changes in renal function remains unclear.
Our study results show no increase in KIM-1 and N-GAL
excretion post-CE-CT and absence of a predictive value of
these biomarkers for the development of CI-AKI, which is
in contradiction to the literature on N-GAL and KIM-1 excre-
tion after intra-arterial contrast injections. This can be ex-
plained as follows. First, percutaneous coronary intervention
and other procedures requiring intra-arterial contrast adminis-
trations bring along procedural related risk factors for AKI,
such as cholesterol emboli shedding into the renal vasculature
by catheterization of the descending aorta [32–34]. Second,
patients undergoing percutaneous coronary interventions
might experience hemodynamic instability as a pre-renal
cause of AKI, since acute myocardial infarction is one of the
main indications for this procedure. Third, suprarenally
injected contrast boluses, as used for radial percutaneous
coronary interventions, might be more concentrated and,
therefore, nephrotoxic than intravenously injected boluses
when they arrive at the level of the kidney. Fourth, patients
undergoing CE-CT might differ from patients undergoing
intra-arterial contrast administrations in terms of the presence
of comorbidity at risk of developing CI-AKI, such as diabetes
mellitus [35]. These differences in patient characteristics may
also affect KIM-1 and N-GAL expression after administration
of iodinated contrast media. Although the results of our study
can’t designate by which mechanism the risk of tubular injury
varies after intravenous and intra-arterial contrast administra-
tion, they do suggest that the performance of CE-CT in CKD
patients is likely to be safe. This finding endorses the recom-
mendation of the CI-AKI guideline of the American College
of Radiology to withhold preventive hydration in CKD pa-
tients undergoing CE-CT.
Our study, therefore, adds clinically relevant information to
the research field. To our knowledge, this is the first study
Fig. 3 Figures reflect N-GAL excretions in patients with (in green) and patients without (in blue) contrast-induced acute kidney injury at A) baseline, B)
4 – 6 h, and C) 48 – 96 h post-intravenous contrast-enhanced computed tomography
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analyzing both KIM-1 and N-GAL expression post-CE-CT. We
analyzed these two established biomarkers of CI-AKI within
adequate time frames, as indicated by previous studies [11, 14].
Moreover, due to the prospective study design, all relevant infor-
mation on co-morbidity influencing our outcomes was available
for analysis. However, some aspects of our study require com-
ment. We included a population with mainly moderate CKD
since only 7 % of patients had a baseline eGFR value of less
than 30 ml/min. Therefore, we can’t exclude the possibility of
some extent of tubular injury post CE-CT in patients with severe
CKD. However, that group reflects only 10 % of CKD patients
undergoing CE-CT in daily practice [36]. Moreover, our sample
size was too small to study differences in KIM-1 and N-GAL
expression between different types of contrast media.
In conclusion, KIM-1 and N-GAL excretion were unaffect-
ed by CE-CT in both patients with and without CI-AKI. This
study suggests that CE-CT can probably be safely performed
in patients with CKD, and challenges the creatinine based
definition of CI-AKI.
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